AXIM Biotechnologies, Inc. AXIM

AXIM Company Overview

AXIM Biotechnologies, Inc. (OTCQB: AXIM) is a biotechnology and diagnostic research company focused on developing rapid diagnostic testing technologies and proprietary pharmaceutical and nutraceutical products. The company has historically operated in the healthcare and biotechnology sectors, with activities centered on ocular disease diagnostics, immunology-related testing, and cannabinoid-based research initiatives. Public filings and company disclosures indicate that AXIM’s primary strategic focus has shifted over time toward in vitro diagnostic technologies, particularly lateral flow assays and rapid testing platforms.

The company’s principal business activities have included the development of diagnostic products for dry eye disease and inflammatory conditions, as well as intellectual property associated with cannabinoid-based formulations. AXIM has pursued commercialization through research collaborations, licensing arrangements, and subsidiary-led development programs. Historically, the company evolved from a broader cannabinoid therapeutics and nutraceutical strategy into a diagnostics-oriented biotechnology enterprise, reflecting changing market conditions and regulatory considerations in the healthcare and life sciences industries.